Genentech’s (DNA) for Q2 hit $3 billion, up from $2.2 billion in the same quarter last year. Operating income hit $1.1 billion up from $.75 billion last year.
Big winners in the company’s drug portfolio were Avastin with sales up 33% to $564 million in US product sales and Lucentis, introduced recently with sales of $209 million.
Sales of the company’s No.1 product, Rituxan, were up 11% to $562.
The shares traded flat after hours.
Douglas A. McIntyre
An
Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
